TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8736279
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 25 ng/kg/min for 30 minutes
Study: 7577887
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion
Study: 1895900
Drug: OTM-01A ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTM-01A ophthalmic tonometer
Study: 6624778
Drug: Aerosol albuterol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol albuterol (3 puffs)
Study: 6624778
Drug: Oral aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aminophylline (400 mg) and terbutaline sulfate (5 mg)
Study: 27610741
Drug: Modular evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular evidence-based treatment targeting comorbid mental health problems
Study: 27610741
Drug: Modular evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modular evidence-based treatment focusing on principal clinical problems
Study: 18990168
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (control)
Study: 9327366
Drug: Spray-dried bovine
Normalized name: thrombin, bovine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-dried bovine serum concentrate (25% replacement of milk protein)
Study: 9327366
Drug: Spray-dried bovine
Normalized name: thrombin, bovine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-dried bovine serum concentrate (50% replacement of milk protein)
Study: 9327366
Drug: Spray-dried bovine
Normalized name: thrombin, bovine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray-dried bovine serum concentrate (25% and 50% replacement)
Study: 8227760
Drug: Disulfiram (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (800 mg) during dexamethasone and postdexamethasone days
Study: 31339403
Drug: Group‐task‐oriented training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group‐task‐oriented training (group‐TOT) for 1 hour, twice a week for 8 weeks
Study: 31339403
Drug: Individualized traditional
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized traditional physical and occupational therapy (comparison group)
Study: 27544584
Drug: qHPV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHPV vaccine (0.5mL) administered intramuscularly at months 0, 2, and 6
Study: 22736125
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day of bowel preparation
Study: 22736125
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of bowel preparation
Study: 18676533
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 mL daily from week 18 of pregnancy until 3 months after delivery)
Study: 18676533
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (10 mL daily from week 18 of pregnancy until 3 months after delivery)
Study: 24874315
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (240 mg per day for 24 weeks)
Study: 24874315
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs (control group)
Study: 28105515
Drug: Azosemide (long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azosemide (long-acting loop diuretic)
Study: 17587724
Drug: Furosemide (short-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (short-acting loop diuretic)
Study: 18300446
Drug: 24-hour pH
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour pH monitoring with antacid treatment (omeprazole)
Study: 18300446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with antacid treatment (omeprazole) only
Study: 2533866
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms of B‐Hepavac II vaccine
Study: 2533866
Drug: 5 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 micrograms of B‐Hepavac II vaccine
Study: 779705
Drug: Methadyl acetate
Normalized name: Methadyl acetate
DrugBank: Methadyl acetate (DB01433)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadyl acetate (80 mg three times a week)
Study: 779705
Drug: High-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methadone (50 mg daily or 100 mg daily)
Study: 21076361
Drug: Low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methadone
Study: 28472530
Drug: Nutrition intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition intervention for 3 months with individualized nutrition care plan plus monthly post-discharge telehealth follow-up
Study: 23147558
Drug: SRP+SDD (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP+SDD (20 mg of doxycycline twice daily)
Study: 17519642
Drug: Olanzapine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (2.5 mg for 1 month, 5 mg for 2 months)
Study: 17519642
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy + Olanzapine
Study: 11423814
Drug: Intravenous pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pyridoxine (5 g over 5 minutes)
Study: 11423814
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo (50 mL of normal saline solution)
Study: 8094168
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg aspirin daily until delivery
Study: 31940793
Drug: Convolutional neural
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Convolutional neural network for PPI site prediction; improved data set; specific details on dosage and duration not applicable.
Study: 9249121
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg)
Study: 26938140
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g)
Study: 26938140
Drug: Morphine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1 mg/kg) and Acetaminophen (1 g)
Study: 23263176
Drug: Early antiretroviral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antiretroviral therapy (ART) initiated at enrollment (n = 139)
Study: 23263176
Drug: Deferred antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred antiretroviral therapy (ART) initiated when CD4 count <15% or CDC category C event developed (n = 145)
Study: 21463065
Drug: Oxycodone 20
Normalized name: oxycodone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 20 mg
Study: 21395483
Drug: Oxycodone/Naloxone 20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Naloxone 20/10 mg
Study: 31764725
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg
Study: 10634373
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (600 mg/day)
Study: 18339123
Drug: Melatonin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (3 mg/day) and Vitamin E (600 mg/day)
Study: 18339123
Drug: No melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No melatonin treatment
Study: 16797388
Drug: GLA 2.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA 2.2% cream
Study: 16797388
Drug: Placebo-based cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-based cream
Study: 12506030
Drug: Donor pretransplantation
Normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor pretransplantation antibody levels
Study: 12506030
Drug: Patient or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient or donor age, total body irradiation, and graft‐versus‐host disease or its treatment
Study: 10730983
Drug: Continuous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous oxytocin infusion (1:9 mg/d) on Days 14 to 26 after estrus
Study: 10730983
Drug: Oxytocin injections
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin injections (0.33 USP units/kg body weight, s.c.) twice daily on Days 3 to 6 of the estrous cycle
Study: 1466940
Drug: Ketotifen (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (0.5 mg) syrup, 2.5 mL twice daily
Study: 1466940
Drug: Placebo syrup,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup, 2.5 mL twice daily
Study: 31907033
Drug: Negative-pressure wound
Normalized name: Microcyn Negative-Pressure Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure wound therapy (NPWT) using the PICO™ system
Study: 26123563
Drug: Tenofovir gel
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir gel
Study: 15356495
Drug: Extended prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended prophylaxis regimen including regular mechanical tooth cleaning by a hygienist, scaling, and chlorhexidine treatment.
Study: 15356495
Drug: Initial prophylaxis
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial prophylaxis alone consisting of patient motivation, oral hygiene checkups, and fluoridation.
Study: 12073159
Drug: THC-only (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-only (low dose)
Study: 12073159
Drug: THC-only (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC-only (high dose)
Study: 12073159
Drug: Whole-plant marijuana
Normalized name: century plant whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-plant marijuana (low dose)
Study: 12073159
Drug: Whole-plant marijuana
Normalized name: century plant whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-plant marijuana (high dose)
Study: 10445600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group A: Low dose inhaled corticosteroids (< or =400 microg/day)
Study: 10445600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group B: Oral corticosteroids (> or =10 mg/day)
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection with live spermatozoa
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection with dead spermatozoa
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection without a spermatozoon
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection of human sperm cytosolic fraction (CF)
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection of human sperm cytosolic fraction (CF) in mouse oocytes
Study: 7769071
Drug: Intracytoplasmic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic injection of CF after heat treatment
Study: 2179521
Drug: Haloperidol treatment
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol treatment for 26 days
Study: 6849726
Drug: Methotrimeprazine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrimeprazine 7.5 mg i.m.
Study: 9283163
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg
Study: 6849726
Drug: Methotrimeprazine (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrimeprazine (small non-sedative doses)
Study: 25046950
Drug: Shen‐reinforcing and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shen‐reinforcing and menstrual cycle‐regulating therapy combined with Western medicine (IM group)
Study: 25046950
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM group)
Study: 22296973
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 · 2 mg daily for 6–10 days)
Study: 14715345
Drug: Full-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose reteplase
Study: 14715345
Drug: Half-dose reteplase
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose reteplase with full-dose abciximab
Study: 9297428
Drug: rH‐EPO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rH‐EPO (200 U/kg body weight subcutaneously once a day, three days a week for 4 weeks) with oral ferrous sulfate (4 mg/kg/day)
Study: 7952423
Drug: Early medical
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early medical therapy
Study: 3674795
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine (mode = 13 mg/day)
Study: 2189429
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine
Study: 31942840
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (100 mg) in addition to standard treatment
Study: 12577242
Drug: Amifostine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (200 mg/m2/d before radiation)
Study: 12577242
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (radiation therapy 64.8 Gy, paclitaxel, carboplatin, followed by cisplatin and gemcitabine)
Study: 15335530
Drug: 0.05% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% aqueous alcohol solution (1 ml)
Study: 15335530
Drug: 0.10% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.10% aqueous alcohol solution (1 ml)
Study: 15335530
Drug: 0.15% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% aqueous alcohol solution (1 ml)
Study: 7975842
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine expressed in mutant yeast (non-hyperglycosylated preS2 + 2 polypeptide)
Study: 7975842
Drug: Licensed HB
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed HB vaccine
Study: 7975842
Drug: Hyperglycosylated preS2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycosylated preS2 + 2 vaccine
Study: 28761069
Drug: Biomarker-positive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-positive patients receiving FDA-approved oncology drugs with required pharmacogenomic biomarker testing
Study: 15389187
Drug: Infliximab 3
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 3 mg/kg
Study: 15389187
Drug: Infliximab 5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg
Study: 19203570
Drug: diclofenac-cholestyramine 140
Normalized name: cholestyramine resin / diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac-cholestyramine 140 mg capsule formulation
Study: 17363401
Drug: 110 mg
Normalized name: lactase 110 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 mg epicutaneous ketoprofen in 4.8 g Transfersome
Study: 17363401
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral celecoxib
Study: 15371062
Drug: Client-centered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered therapy for childhood traumatic grief (CTG)
Study: 11430439
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity laser therapy (830nm) at a dosage of 9 J/cm2
Study: 2297460
Drug: Oxazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (15 mg) + Propranolol (80 mg)
Study: 2297460
Drug: Oxazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (15 mg) + Labetalol (200 mg)
Study: 2297460
Drug: Oxazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (15 mg) + Propranolol (80 mg) + Labetalol (200 mg)
Study: 2793265
Drug: Labetalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (200 mg)
Study: 28659293
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg Fe · kg‐1 · d‐1
Study: 28659293
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Fe · kg‐1 · d‐1
Study: 28659293
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (combined 1 or 2 mg Fe · kg‐1 · d‐1)
Study: 25952050
Drug: Experimental handwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental handwash formulations (sand)
Study: 6361287
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methylprednisolone
Study: 9489539
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with preceding gastrointestinal illness, initial predominant distal weakness, acute motor neuropathy, or anti-GM1 antibodies
Study: 9489539
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with treatment related fluctuations
Study: 1537493
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal in combination with propranolol
Study: 6373157
Drug: oxpentifylline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxpentifylline (200 mg 3-times daily)
Study: 31148494
Drug: Radial Shockwave
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial Shockwave Therapy (rSWT) + Standard Orthotic Management (SOM)
Study: 29557855
Drug: Long-term medication-assisted
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medication-assisted treatment (LT-MAT) with buprenorphine/naloxone
Study: 29557855
Drug: Short-term medication-assisted
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term medication-assisted treatment (C)
Study: 20961967
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg/day, n=34)
Study: 20961967
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/day, n=33)
Study: 31563388
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS treatment
Study: 20633407
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS treatment
Study: 17701857
Drug: Sonographic examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sonographic examination after 3 months of abstinence therapy
Study: 14675243
Drug: PFL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFL therapy (13 mg/m2 CDDP, 300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Study: 14675243
Drug: FL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL therapy (300 mg/m2 5-FU, 30 mg/body weight LV for 5 consecutive days)
Study: 14675243
Drug: FL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL therapy
Study: 14675243
Drug: PFL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFL therapy
Study: 14675243
Drug: PFL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFL therapy and FL therapy
Study: 11399714
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (RBC transfusions at hemoglobin concentration of 7.0 g/dL, maintained between 7.0 g/dL and 9.0 g/dL)
Study: 11399714
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (RBC transfusions at hemoglobin concentration of 10.0 g/dL, maintained between 10.0 g/dL and 12.0 g/dL)
Study: 9579845
Drug: Combined intravenous
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravenous and intraperitoneal chemotherapy with FU/LV (LV 200 mg m(‐2) plus FU 350 mg m(‐2), administered intravenously on days 1-4 and intraperitoneally on days 1 and 3 every 4 weeks for a total of six courses)
Study: 9579845
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with FU and levamisole (given for a duration of 6 months)
Study: 7660219
Drug: Methimazole 30
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 30 mg once daily
Study: 7660219
Drug: Propylthiouracil 100
Normalized name: propylthiouracil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propylthiouracil 100 mg every 8 hours
Study: 25988924
Drug: Review of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Review of clinical features, treatment, and prognosis
Study: 19278581
Drug: Thymosin alpha1
Normalized name: Thymosin alpha1 (human)
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin alpha1 (1.6 mg subcutaneous injection per day for 7 days)
Study: 19278581
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (CBP + thymosin alpha1)